Skip to main content
    N

    NeoGenomics Inc (NEO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $16.02
    -0.52 (-3.14%)

    Market Cap: $2.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    NeoGenomics Inc (NEO) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    NeoGenomics (NEO) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, NeoGenomics reported EPS of $0.01, above the -$0.01 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    86%(32/37)
    Avg Surprise
    +32.06%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.07
    Range$0.05 - $0.09
    13 analysts
    Revenue Consensus
    $212.06M
    Range$200.02M - $221.76M
    13 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.05
    Range$0.01 - $0.09
    10 analysts
    EPS Revisions
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.06-8.5%
    60d ago$0.06-8.5%
    30d ago$0.06-8.5%
    7d ago$0.06-2.9%
    Current$0.05
    Revenue Consensus
    $206.43M
    Range$203.14M - $209.03M
    10 analysts

    Next Report

    NEO has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.7% above the $0.06 reported for the quarter ended Dec 31, 2025.

    NEO Earnings Call

    The latest NEO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, NEO beat 32, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $209.25M, up 11.4% from $187.80M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.01-$0.01N/A+200.00%Beat-66.7%112 up, 1 downOct 28, 2026$209.25M
    Jun 30, 2026-$0.01-$0.06N/A+83.33%Beat-133.3%110 up, 1 downJul 28, 2026$201.66M
    Mar 31, 2026$0.01$0.01-$0.03 - $0.02-12.28%MissN/A91 up, 5 downApr 28, 2026$186.67M
    Dec 31, 2025$0.06$0.04$0.01 - $0.06+50.00%Beat+50.0%121 up, 0 downFeb 17, 2026$190.17M
    Sep 30, 2025$0.03$0.02$0.01 - $0.05+50.00%BeatN/A130 up, 12 downOct 28, 2025$187.80M
    Jun 30, 2025$0.03$0.02$0.01 - $0.06+50.00%Beat0.0%130 up, 2 downJul 29, 2025$181.33M
    Mar 31, 2025-$0.20-$0.01-$0.02 - $0.03N/AN/AN/A120 up, 1 downApr 29, 2025$168.03M
    Dec 31, 2024$0.04$0.03$0.01 - $0.07+39.86%Beat+33.3%141 up, 0 downFeb 18, 2025$172.00M
    Sep 30, 2024-$0.14$0.01-$0.03 - $0.05N/AN/AN/A141 up, 0 downNov 5, 2024$167.82M
    Jun 30, 2024$0.03$0.00-$0.03 - $0.02N/AN/AN/A130 up, 0 downJul 29, 2024$164.50M
    Mar 31, 2024-$0.02-$0.05-$0.11 - -$0.02+60.00%BeatN/A110 up, 0 downApr 30, 2024$156.24M
    Dec 31, 2023$0.03-$0.03-$0.10 - $0.00+200.00%BeatN/A131 up, 0 downFeb 20, 2024$155.55M
    Sep 30, 2023-$0.02-$0.08-$0.16 - -$0.05+75.00%BeatN/A121 up, 0 downNov 6, 2023$151.95M
    Jun 30, 2023-$0.05-$0.11-$0.15 - -$0.08+54.55%BeatN/A131 up, 0 downAug 8, 2023$146.92M
    Mar 31, 2023-$0.09-$0.15-$0.27 - -$0.06+40.00%BeatN/A131 up, 0 downMay 8, 2023$137.22M
    Dec 31, 2022-$0.06-$0.16-$0.27 - -$0.10+62.50%BeatN/A130 up, 0 downFeb 23, 2023$138.71M
    Sep 30, 2022-$0.14-$0.21-$0.25 - -$0.15+33.33%BeatN/A131 up, 0 downNov 8, 2022$128.78M
    Jun 30, 2022-$0.16-$0.23-$0.28 - -$0.16+30.43%BeatN/A130 up, 0 downAug 9, 2022$125.07M
    Mar 31, 2022-$0.20-$0.24-$0.29 - -$0.18+16.67%BeatN/A120 up, 1 downApr 27, 2022$117.17M
    Dec 31, 2021-$0.14-$0.15-$0.22 - -$0.10+6.67%Beat-200.0%11N/AFeb 23, 2022$125.73M
    Sep 30, 2021-$0.08-$0.09-$0.14 - -$0.01+11.11%Beat-233.3%12N/ANov 4, 2021$121.34M
    Jun 30, 2021-$0.01-$0.06-$0.13 - $0.01+83.33%BeatN/A12N/AAug 6, 2021$121.72M
    Mar 31, 2021-$0.04$0.01-$0.03 - $0.04-500.00%MissN/A11N/AMay 5, 2021$115.53M
    Dec 31, 2020$0.14$0.06$0.03 - $0.09+133.33%Beat+40.0%11N/AFeb 24, 2021$126.00M
    Sep 30, 2020$0.06$0.04-$0.06 - $0.11+50.00%Beat-14.3%10N/AOct 27, 2020$125.44M
    Jun 30, 2020-$0.04-$0.10-$0.17 - -$0.05+60.00%Beat-157.1%8N/AJul 28, 2020$86.98M
    Mar 31, 2020-$0.02$0.02$0.01 - $0.03-200.00%Miss-128.6%9N/AApr 28, 2020$106.03M
    Dec 31, 2019$0.10$0.06$0.05 - $0.09+66.67%Beat+66.7%7N/AFeb 27, 2020$106.87M
    Sep 30, 2019$0.07$0.06$0.05 - $0.07+16.67%Beat+40.0%8N/AOct 29, 2019$104.67M
    Jun 30, 2019$0.07$0.06$0.05 - $0.07+16.67%Beat+40.0%8N/AJul 30, 2019$101.71M
    Mar 31, 2019$0.07$0.04$0.03 - $0.07+75.00%Beat+75.0%8N/AApr 30, 2019$95.58M
    Dec 31, 2018$0.06$0.04$0.04 - $0.08+50.00%Beat+20.0%9N/AFeb 19, 2019$76.47M
    Sep 30, 2018$0.05$0.02$0.01 - $0.04+150.00%Beat+400.0%8N/AOct 30, 2018$69.10M
    Jun 30, 2018$0.05$0.04$0.04 - $0.05+25.00%Beat+25.0%6N/AJul 24, 2018$67.75M
    Mar 31, 2018$0.04$0.03$0.03 - $0.03+33.33%Beat+33.3%6N/AMay 1, 2018$63.42M
    Dec 31, 2017$0.05$0.04$0.03 - $0.05+25.00%Beat0.0%8N/AFeb 21, 2018$67.79M
    Sep 30, 2017$0.01$0.02$0.01 - $0.05-50.00%Miss-75.0%9N/AOct 25, 2017$63.05M
    Jun 30, 2017$0.04$0.03$0.03 - $0.04+33.33%Beat0.0%9N/AJul 25, 2017$62.26M
    Mar 31, 2017$0.03$0.03N/A0.00%In line0.0%N/AN/AApr 26, 2017$61.68M
    Dec 31, 2016$0.05$0.03N/A+66.67%BeatN/AN/AN/AFeb 22, 2017$60.49M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.08, after -$0.09 the year before. It was $0.16 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.08N/A
    Dec 31, 2024-$0.09N/A
    Dec 31, 2023-$0.13N/A
    Dec 31, 2022-$0.56N/A
    Dec 31, 2021-$0.27-292.9%
    Dec 31, 2020$0.14-54.8%
    Dec 31, 2019$0.31+55.0%
    Dec 31, 2018$0.20+53.8%
    Dec 31, 2017$0.13N/A
    Dec 31, 2016$0.16N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202610,57516
    2026Q2Jun 30, 20267,72114
    2026Q1Mar 31, 20267,30614
    2025Q4Dec 31, 20256,61910
    2025Q3Sep 30, 20257,88315
    2025Q2Jun 30, 20259,71217
    2025Q1Mar 31, 20259,64719
    2024Q4Dec 31, 20249,22118

    2026Q3 Earnings Call

    Opening remarks

    Andrew Brackmann Vice President of Investor Relations Thank you, Sylvie, and good afternoon, everyone. Representing NeoGenomics here today are Tony Zook, Chief Executive Officer; Warren Stone, President and Chief Operating Officer; and Abhishek Jain, Chief Financial Officer. This call is being simultaneously webcast, and a recording will be available following the conclusion at ir.neogenomics.com. During this call, we will make forward-looking statements regarding our future financial and business performance, our planned leadership transition, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, estimates of market size and position, the implementation of our new revenue cycle management platform and its anticipated benefits and effects on the timing of our collections, objectives of management, and financial guidance. We caution you that the actual events or results could differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements made during the call speak only as of the original date of this call, and we undertake no obligation to update or revise any of these statements. Please refer to the information disclosed on the safe harbor statement slide in the deck posted on our website, as well as the information under the heading Risk Factors in our annual report on Form 10-K and our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC, to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements. These documents can be found in the Investors section of our website or on the SEC's website. During this call, we will also refer to certain non-GAAP financial measures that involve adjustments to our GAAP results. The non-GAAP financial measures presented should not be considered an alternative to the financial measures required by GAAP, should not be considered measures of liquidity, and are unlikely to be comparable to the non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available in the press release we issued earlier today and in the slide deck available in the Investors section of our website. I will now turn the call over to Tony.

    Anthony Zook Chief Executive Officer Thank you, Andrew, and good afternoon, everyone. We're excited to report another strong quarter, which shows we have the right strategy in place, the right team to execute it, and we're delivering consistent results because of this. Our business is continuing to gain momentum, and our third-quarter results show it. Clinical revenue grew 13% year over year.

    Frequently Asked Questions About NEO

    When is NeoGenomics's next earnings date?

    NeoGenomics's next earnings report is expected for Feb 15, 2027.

    Did NEO beat earnings estimates last quarter?

    Yes. NeoGenomics reported EPS of $0.01 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 200.00% surprise.

    What EPS do analysts expect from NEO next quarter?

    The consensus EPS estimate for NeoGenomics for the quarter ending Dec 31, 2026 is $0.07 from 13 analysts, with estimates from $0.05 to $0.09.

    How often does NEO beat earnings estimates?

    NeoGenomics beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +65.11%.